Plague

ID Biomedical announces additional contract related to a subunit plague vaccine

Published in Vaccine Weekly, December 31st, 2003

ID Biomedical announced that it has received additional funding from Dynport Vaccine Co., LLC, (DVC) relating to the development of a second-generation, subunit plague vaccine.

The additional contract and amendments to the first contract will provide ID Biomedical with approximately US$4.5 million for further process development and manufacturing activities related to producing a subunit recombinant plague antigen under current good manufacturing practices. This second contract brings DVC's approximate total funding commitment to ID Biomedical to up to US$10.6 million for this program.

The plague, also known as "the Black Death," is caused by...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2003-12-31)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry